Profile of darunavir in the management of treatment-experienced HIV patients

Profile of darunavir in the management of treatment-experienced HIV patients

Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding...

Full description

Bibliographic Details
Main Authors: Cameron Wolfe, Charles Hicks
Format: Article
Language:English
Published: Dove Medical Press 2009-09-01
Series:HIV/AIDS : Research and Palliative Care
Online Access:http://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582
id doaj-f8f886a94fd04aa68ae968125536033c
record_format Article
spelling doaj-f8f886a94fd04aa68ae968125536033c2020-11-25T00:31:01ZengDove Medical PressHIV/AIDS : Research and Palliative Care1179-13732009-09-012009Default1321Profile of darunavir in the management of treatment-experienced HIV patientsCameron WolfeCharles HicksCameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavir http://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582
collection DOAJ
language English
format Article
sources DOAJ
author Cameron Wolfe
Charles Hicks
spellingShingle Cameron Wolfe
Charles Hicks
Profile of darunavir in the management of treatment-experienced HIV patients
HIV/AIDS : Research and Palliative Care
author_facet Cameron Wolfe
Charles Hicks
author_sort Cameron Wolfe
title Profile of darunavir in the management of treatment-experienced HIV patients
title_short Profile of darunavir in the management of treatment-experienced HIV patients
title_full Profile of darunavir in the management of treatment-experienced HIV patients
title_fullStr Profile of darunavir in the management of treatment-experienced HIV patients
title_full_unstemmed Profile of darunavir in the management of treatment-experienced HIV patients
title_sort profile of darunavir in the management of treatment-experienced hiv patients
publisher Dove Medical Press
series HIV/AIDS : Research and Palliative Care
issn 1179-1373
publishDate 2009-09-01
description Cameron Wolfe, Charles HicksDuke University Medical Center, Division of Infectious Diseases, Durham, NC, USAAbstract: Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.Keywords: darunavir, HIV, ritonavir
url http://www.dovepress.com/profile-of-darunavir-in-the-management-of-treatment-experienced-hiv-pa-a3582
work_keys_str_mv AT cameronwolfe profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients
AT charleshicks profileofdarunavirinthemanagementoftreatmentexperiencedhivpatients
_version_ 1725324269135593472

Similar Items